scholarly journals Endothelial Progenitor Cells in Diabetic Microvascular Complications: Friends or Foes?

2016 ◽  
Vol 2016 ◽  
pp. 1-10 ◽  
Author(s):  
Cai-Guo Yu ◽  
Ning Zhang ◽  
Sha-Sha Yuan ◽  
Yan Ma ◽  
Long-Yan Yang ◽  
...  
Keyword(s):  
Progenitor Cells ◽  
Endothelial Progenitor Cells ◽  
Microvascular Complications ◽  
Microvascular Disease ◽  
Diabetic Patients ◽  
Endothelial Progenitor ◽  
Vascular Abnormality ◽  
Diabetic Microvascular Complications ◽  
Angiopoietin 2 ◽  
And Function

Despite being featured as metabolic disorder, diabetic patients are largely affected by hyperglycemia-induced vascular abnormality. Accumulated evidence has confirmed the beneficial effect of endothelial progenitor cells (EPCs) in coronary heart disease. However, antivascular endothelial growth factor (anti-VEGF) treatment is the main therapy for diabetic retinopathy and nephropathy, indicating the uncertain role of EPCs in the pathogenesis of diabetic microvascular disease. In this review, we first illustrate how hyperglycemia induces metabolic and epigenetic changes in EPCs, which exerts deleterious impact on their number and function. We then discuss how abnormal angiogenesis develops in eyes and kidneys under diabetes condition, focusing on “VEGF uncoupling with nitric oxide” and “competitive angiopoietin 1/angiopoietin 2” mechanisms that are shared in both organs. Next, we dissect the nature of EPCs in diabetic microvascular complications. After we overview the current EPCs-related strategies, we point out new EPCs-associated options for future exploration. Ultimately, we hope that this review would uncover the mysterious nature of EPCs in diabetic microvascular disease for therapeutics.

scholarly journals Quantitative and functional evaluation of endothelial progenitor cells in patients with cardiac amyloidosis

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
O Itzhaki Ben Zadok ◽  
D Leshem-Lev ◽  
T Ben-Gal ◽  
A Hamdan ◽  
N Schamroth-Pravda ◽  
...  
Keyword(s):  
Progenitor Cells ◽  
Endothelial Progenitor Cells ◽  
Mtt Assay ◽  
Cardiac Amyloidosis ◽  
Microvascular Dysfunction ◽  
Functional Evaluation ◽  
Endothelial Progenitor ◽  
Colony Forming Units ◽  
Study Population ◽  
And Function

Abstract Background Endothelial microvascular dysfunction is a known mechanism of injury in cardiac amyloidosis (CA), but evidence regarding the level and function of endothelial progenitor cells (EPCs) in patients with CA is lacking. Methods Study population included patients with light-chain or transthyretin (ATTR) CA. Patients with diagnosed heart failure and preserved ejection fraction (HFpEF) without monoclonal gammopathy and a 99mTc-DPD scan incompatible with TTR were used as controls. Blood circulating EPCs were assessed quantitatively by the expression of VEGFR-2(+), CD34(+) and CD133(+) using flow cytometry, and functionally by the formation of colony forming units (CFUs). MTT assay was used to demonstrate cell viability. Tests were repeated 3 months following the initiation of amyloid-suppressive therapies (either ATTR-stabilizer or targeted chemotherapy) in CA patients. Results Our preliminary cohort included 14 CA patients (median age 74 years, 62% ATTR CA). Patients with CA vs. patients with HFpEF (n=8) demonstrated lower expression of CD34(+)/VEGFR-2(+) cells [0.51% (IQR 0.4, 0.7) vs. 1.03% (IQR 0.6, 1.4), P=0.043] and CD133(+)/VEGFR-2(+) cells [0.35% (IQR 0.23, 0.52) to 1.07% (IQR 0.6, 1.5), P=0.003]. Functionally, no differences were noted between groups. Following the initiation of amyloid-suppressive therapies in CA patients, we observed the up-regulation of CD34(+)/VEGFR-2(+) cells [2.47% (IQR 2.1, 2.7), P<0.001] and CD133(+)/VEGFR-2(+) cells [1.38% (IQR 1.1, 1.7), P=0.003]. Moreover, functionally, active EPCs were evident microscopically by their ability to form colonies (from 0.5 CFUs [IQR 0, 1.5) to 2 CFUs (IQR 1, 3.5), P=0.023]. EPCs' viability was demonstrated by an MTT assay [0.12 (IQR 0.04, 0.12) to 0.24 (IQR 0.16, 0.3), p=0.014]. Conclusions These preliminary results demonstrate reduced EPCs levels in CA patients indicating significant microvascular impairment. Amyloid-targeted therapies induce the activation of EPCs, thus possibly promoting endothelial regeneration. These findings may represent a novel mechanism of action of amyloid-suppressive therapies EPCs in CA patients and during therapy Funding Acknowledgement Type of funding source: None

Periodontal treatment modulates gene expression of endothelial progenitor cells in diabetic patients

2017 ◽  
Vol 44 (12) ◽  
pp. 1253-1263 ◽  
Author(s):  
Yi Wang ◽  
Hin Nam Liu ◽  
Zhe Zhen ◽  
Kai Hang Yiu ◽  
Hung Fat Tse ◽  
...  
Keyword(s):  
Gene Expression ◽  
Progenitor Cells ◽  
Endothelial Progenitor Cells ◽  
Periodontal Treatment ◽  
Diabetic Patients ◽  
Endothelial Progenitor

scholarly journals Decreased Count and Dysfunction of Circulating EPCs in Postmenopausal Hypercholesterolemic Females via Reducing NO Production

2018 ◽  
Vol 2018 ◽  
pp. 1-10 ◽  
Author(s):  
Ying Luo ◽  
Quan-Neng Yan ◽  
Wan-Zhou Wu ◽  
Fan-Yan Luo
Keyword(s):  
Endothelial Dysfunction ◽  
Progenitor Cells ◽  
Endothelial Progenitor Cells ◽  
Therapeutic Strategy ◽  
No Production ◽  
Endothelial Progenitor ◽  
Endothelial Repair ◽  
Flow Mediated Dilatation ◽  
Premenopausal Female ◽  
And Function

Endothelial progenitor cells (EPCs) contribute to the endogenous endothelial repair program during hypercholesterolemia. EPC count and migratory and proliferative capacities remain unchanged in the premenopausal female with hypercholesterolemia. However, the changes of count and activity of circulating EPCs in the hypercholesterolemic postmenopausal females are unknown. Here, we find that the migratory and proliferative capacities of circulating EPCs were decreased in patients with hypercholesterolemia versus normocholesterolemia. No significant differences were found between postmenopausal females and age-matched males. NO production showed positive correlation with the activity and count of circulating EPCs in patients with hypercholesterolemia. Flow-mediated dilatation (FMD) is directly interrelated with EPC counts and function. Our findings reveal that decreased EPC count and endothelial dysfunction lead to less NO production in hypercholesterolemic postmenopausal females. Maintaining the EPC numbers and activity might be emerging as a potential therapeutic strategy to reduce the risk of cardiovascular injury in elder women.

Characteristics and Function of Cryopreserved Bone Marrow–Derived Endothelial Progenitor Cells

2008 ◽  
Vol 85 (4) ◽  
pp. 1361-1366 ◽  
Author(s):  
Shigetoshi Mieno ◽  
Richard T. Clements ◽  
Munir Boodhwani ◽  
Neel R. Sodha ◽  
Basel Ramlawi ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Progenitor Cells ◽  
Endothelial Progenitor Cells ◽  
Endothelial Progenitor ◽  
And Function

Circulating endothelial progenitor cells in type 1 diabetic patients with erectile dysfunction

Endocrine ◽  
2014 ◽  
Vol 49 (2) ◽  
pp. 415-421 ◽  
Author(s):  
Maria Ida Maiorino ◽  
Giuseppe Bellastella ◽  
Michela Petrizzo ◽  
Elisabetta Della Volpe ◽  
Rosanna Orlando ◽  
...  
Keyword(s):  
Erectile Dysfunction ◽  
Progenitor Cells ◽  
Endothelial Progenitor Cells ◽  
Diabetic Patients ◽  
Endothelial Progenitor ◽  
Circulating Endothelial Progenitor Cells ◽  
Type 1 Diabetic Patients

Decreased number and function of endothelial progenitor cells in patients with migraine

Neurology ◽  
2008 ◽  
Vol 70 (17) ◽  
pp. 1510-1517 ◽  
Author(s):  
S. -T. Lee ◽  
K. Chu ◽  
K. -H. Jung ◽  
D. -H. Kim ◽  
E. -H. Kim ◽  
...  
Keyword(s):  
Progenitor Cells ◽  
Endothelial Progenitor Cells ◽  
Endothelial Progenitor ◽  
And Function
Sign in / Sign up

Export Citation Format

Share Document